On February 10, Skadden presented “Merger Control and Foreign Investment Reviews,” part two of our Pharmaceutical and Medical Device Webinar Series. Skadden antitrust/competition partner Ingrid Vandenborre was joined by Ling Zeng, chief legal officer and secretary of Dicerna Pharmaceuticals, Inc., and Oliver Latham, a vice president in Charles River Associates’ European Competition Practice. The panelists discussed how to complete pharmaceutical and medical device transactions under the rapidly developing framework for merger control and foreign investment reviews.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates